NEW YORK (GenomeWeb) – Biocartis said today that its tissue-based Idylla NRAS-BRAF mutation test has been CE marked and can now be sold throughout the European Economic Area.

According to the company, the combination of the new NRAS-BRAF mutation test with its existing KRAS assay means that it can offer customers a complete solution for clinical testing of metastatic colorectal cancers, as recommended by the most recent professional guidelines.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.